Editas Medicine Inc (EDIT) CEO Katrine Bosley Sells 8,333 Shares of Stock

Editas Medicine Inc (NASDAQ:EDIT) CEO Katrine Bosley sold 8,333 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $36.18, for a total value of $301,487.94. Following the transaction, the chief executive officer now owns 1,338,898 shares of the company’s stock, valued at approximately $48,441,329.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Katrine Bosley also recently made the following trade(s):

  • On Tuesday, January 30th, Katrine Bosley sold 20,000 shares of Editas Medicine stock. The stock was sold at an average price of $38.79, for a total value of $775,800.00.
  • On Tuesday, January 23rd, Katrine Bosley sold 3,338 shares of Editas Medicine stock. The shares were sold at an average price of $35.28, for a total value of $117,764.64.
  • On Wednesday, January 3rd, Katrine Bosley sold 14,995 shares of Editas Medicine stock. The shares were sold at an average price of $34.15, for a total value of $512,079.25.
  • On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $29.58, for a total value of $246,490.14.

Shares of Editas Medicine Inc (NASDAQ:EDIT) opened at $33.98 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. Editas Medicine Inc has a 52 week low of $13.12 and a 52 week high of $41.60. The company has a market capitalization of $1,500.00 and a price-to-earnings ratio of -10.49.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The company had revenue of $6.28 million for the quarter, compared to analyst estimates of $2.66 million. During the same period last year, the firm earned ($0.59) earnings per share. The firm’s revenue for the quarter was up 553.0% on a year-over-year basis. analysts anticipate that Editas Medicine Inc will post -2.92 EPS for the current year.

Several institutional investors have recently made changes to their positions in EDIT. State Street Corp grew its stake in shares of Editas Medicine by 305.4% during the second quarter. State Street Corp now owns 537,640 shares of the company’s stock worth $9,022,000 after purchasing an additional 405,022 shares during the period. American Century Companies Inc. acquired a new stake in shares of Editas Medicine during the third quarter worth $7,497,000. Ark Investment Management LLC grew its stake in shares of Editas Medicine by 121.9% during the second quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock worth $8,561,000 after purchasing an additional 280,265 shares during the period. Northern Trust Corp grew its stake in shares of Editas Medicine by 245.9% during the second quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock worth $6,261,000 after purchasing an additional 265,273 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Editas Medicine by 12.5% during the second quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock worth $36,533,000 after purchasing an additional 241,973 shares during the period. 64.45% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have issued reports on the company. BidaskClub upgraded Editas Medicine from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. SunTrust Banks upgraded Editas Medicine from a “hold” rating to a “buy” rating and lifted their price objective for the company from $17.00 to $45.00 in a research report on Tuesday, January 23rd. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. ValuEngine downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Cann reissued a “hold” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $30.73.

TRADEMARK VIOLATION WARNING: “Editas Medicine Inc (EDIT) CEO Katrine Bosley Sells 8,333 Shares of Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/06/editas-medicine-inc-edit-ceo-katrine-bosley-sells-8333-shares-of-stock.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply